Targacept's neuro modulator works in exploratory asthma trial, but not in diabetes
This article was originally published in Scrip
Executive Summary
In reporting top-line results, Targacept said its second alpha-7 neuronal nicotinic receptor (NNR) modulator, TC-6987, worked in an exploratory Phase II trial in asthma, but did not show efficacy as a potential treatment for type 2 diabetes.